Expert Insights

Videos

FDA Approval Expands Isatuximab Delivery Options in Multiple Myeloma

08/07/2026

Sikander Ailawadhi, MD

Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...

Sikander Ailawadhi, MD,...

08/07/2026

Oncology

Videos

Subcutaneous Amivantamab Shows Promise in Previously Treated HPV-Negative Head and Neck Cancer

08/06/2026

Barbara Burtness, MD, FASCO

Barbara Burtness, MD, discusses results from cohort 1 of the phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in previously treated HPV-negative head and neck squamous cell carcinoma, highlighting encouraging response rates,...

Barbara Burtness, MD, discusses...

08/06/2026

Oncology

Podcasts

Real-World Decision Points in Biomarker-Driven NSCLC Management

08/05/2026

Jamie Chaft, MD

Dr Jamie Chaft discusses how longitudinal biomarker assessment can support treatment planning, resistance evaluation, and rebiopsy decision-making in NSCLC. Key topics include disease progression, tissue limitations, prior assay results,...

Dr Jamie Chaft discusses how...

08/05/2026

Oncology

Videos

Testing Across the Patient Journey: Longitudinal Biomarker Strategy in NSCLC

08/05/2026

Jamie Chaft, MD

In this video, Jamie Chaft, MD, discusses why biomarker testing in NSCLC should be reassessed over time as clinical questions evolve across diagnosis, treatment response, progression, and later-line decision-making. She highlights the role of...

In this video, Jamie Chaft, MD,...

08/05/2026

Oncology

Podcasts

Connecting the Dots: How MET Fits Into Comprehensive Molecular Profiling

08/05/2026

Jamie Chaft, MD

Dr Jamie Chaft reviews the biological and clinical differences among MET biomarkers in NSCLC, emphasizing the importance of matching the specific biomarker question to the appropriate assay. The discussion covers NGS, IHC, and FISH, as well...

Dr Jamie Chaft reviews the...

08/05/2026

Oncology

Videos

Not All MET Biomarkers Are the Same: Matching the Right Test to the Right Target

08/05/2026

Jamie Chaft, MD

In this video, Jamie Chaft, MD, explains why “MET-positive” is not a single biological category and why clinicians should distinguish among MET exon 14 skipping mutations, MET amplification, c-Met protein overexpression, and MET gene fusions....

In this video, Jamie Chaft, MD,...

08/05/2026

Oncology

Podcasts

Testing Matters: Practical Approaches to Biomarker Evaluation in NSCLC

08/05/2026

Jamie Chaft, MD

Dr Jamie Chaft reviews the importance of early tissue stewardship in NSCLC, including how biopsy planning, tissue adequacy, and coordination across the care team can influence biomarker testing and treatment planning. The discussion...

Dr Jamie Chaft reviews the...

08/05/2026

Oncology

Videos

The Tissue Journey in NSCLC: Why Testing Strategy Starts at Diagnosis

08/05/2026

Jamie Chaft, MD

In this video, Jamie Chaft, MD, discusses why tissue acquisition in NSCLC is more than a diagnostic step—it is the foundation for histologic classification, staging, and comprehensive biomarker testing. She highlights how upfront tissue...

In this video, Jamie Chaft, MD,...

08/05/2026

Oncology

Podcasts

Experienced Dermatologists Continue to Outperform Artificial Intelligence in Skin Cancer Diagnosis

08/04/2026

Luc Thomas, MD, PhD

Luc Thomas, MD, PhD, discusses findings from a real-world study comparing artificial intelligence models with clinicians for skin cancer diagnosis, highlighting the strengths and limitations of artificial intelligence and reinforcing the...

Luc Thomas, MD, PhD, discusses...

08/04/2026

Oncology

Videos

How to Implement Subcutaneous Immunotherapy for Providers

07/30/2026

Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD

The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.

The panel outlines how to...

07/30/2026

Oncology

Recent News

News

IO102-IO103 Plus Nivolumab and Relatlimab Demonstrates Encouraging Activity in Unresectable Melanoma

08/05/2026

Stephanie Holland

A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...

A phase 2 trial demonstrated...

08/05/2026

Oncology

News

HBI-8000 Plus Nivolumab Significantly Improves Progression-Free Survival in Advanced Melanoma

08/05/2026

Stephanie Holland

Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...

Topline results from a global...

08/05/2026

Oncology

FDA Approval

FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases

08/04/2026

Stephanie Holland

The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...

The FDA has approved a rituximab...

08/04/2026

Oncology

FDA Alerts

FDA Advisory Committee Backs RP1 Plus Nivolumab for Advanced Melanoma in 10-3 Vote

07/31/2026

Stephanie Holland

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...

The FDA's Cellular, Tissue, and...

07/31/2026

Oncology

FDA Alerts

Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

07/30/2026

Emily Estrada

The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.

The FDA granted Priority Review...

07/30/2026

Oncology

News

Regorafenib Producess High Response and Durable Disease Control in KIT-Mutant Advanced Melanoma

07/29/2026

Stephanie Holland

The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...

The phase 2 RegoMel trial...

07/29/2026

Oncology

News

Ceralasertib Plus Durvalumab Demonstrates Limited Activity in PD-L1-Resistant Advanced Melanoma

07/29/2026

Stephanie Holland

The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...

The phase 2 MONETTE trial found...

07/29/2026

Oncology

News

Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors

07/28/2026

Emily Estrada

A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...

A real-world study found that...

07/28/2026

Oncology

News

Real-World Study Highlights Evolving Treatment Patterns and Petsistent Diagnostic Challenges in Patients With Desmoid Tumors

07/28/2026

Emily Estrada

Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...

Real-world findings demonstrated...

07/28/2026

Oncology

News

Real-World Analysis Identifies Performance Status as a Key Predictor of Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer

07/28/2026

Stephanie Holland

Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...

Results from the largest...

07/28/2026

Oncology